Search Results

NeoImmuneTech, Inc., announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer of NeoImmuneTech, Inc., effective from March 29, 2024.

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that the European Medicines Agency has granted Orphan Drug Designation to NT-I7 for the treatment of Acute Radiation Syndrome.

NeoImmuneTech, Inc. today presented a poster on a pre-clinical study that opens a new field of potential applications for NT-I7 (efineptakin alfa).

NeoImmuneTech, Inc., a T cell-focused therapeutics company, announced promising interim results of its major clinical trial NIT-110 of NT-I7, at the 2024 American Society of Clinical Oncology global meeting held in Chicago, from May 31 to June 4.

NeoImmuneTech, Inc. announces the appointment of Luke Oh, Ph.D., as President, effective immediately.

NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted NT-I7 (efineptakin alfa) (rhIL-7-hyFc) Orphan Drug Designation (ODD) for the treatment of pancreatic cancer.

Imugene Ltd and NeoImmuneTech, Inc. announced a strategic collaboration to evaluate Imugene’s allogeneic CAR T, azer-cel, in combination with NIT’s proprietary immune T cell amplifier “Fc-fused recombinant human interleukin-7", NT-I7, for the treatment of cancer.

NeoImmuneTech, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for their investigational drug NT-I7 (efineptakin alfa) (rhIL-7-hyFc) for the treatment of Acute Radiation Syndrome (ARS).

NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused biopharmaceutical company, today announced it will present development progress of its main asset, NT-I7 (efineptakin alfa), across two posters at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in San Diego, November 1-5, 2023.